Find support groups, events and resources near you

Additional Testing

Many tests look for genes, proteins, and other substances (called biomarkers) that provide helpful information about a prostate cancer diagnosis.

Doctor with a stethoscope

The most common screening tool for prostate cancer is the prostate-specific antigen (PSA) blood test. This test is usually the first step in any prostate cancer diagnosis. However, the PSA blood test by itself can't tell you if cancer is present.

Recent research has yielded additional tests which look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. These tests, in addition to the PSA, DRE (Digital Rectal Exam), and biopsy, can give doctors and patients more information on how to determine the probability of both finding cancer during a biopsy and determining how aggressive that cancer is likely to be. 

Additional screening and diagnostic tests

While none of these tests are conclusive on their own, when performed in addition to a PSA test, DRE, and a biopsy, they can provide you with more information about your specific cancer and can help in making decisions about your care.

ERG Protein Marker

A marker used on prostate tissue after a biopsy, which measures ERG protein assays. This helps doctors identify patients who have the disease or have pre-cancerous lesions that indicate a patient is more likely to develop prostate cancer over time.

Additional biomarker tests

Biomarker testing may help you and your doctors decide on a treatment. Many prostate cancer biomarker tests are available. Some are used after a biopsy, some are used after a prostatectomy, and some are used if you have localized or advanced prostate cancer. Talk to your doctor about when your tumor should be tested and which biomarker test is right for you.

ProstaVysion®

ProstaVysion is a test that looks for two prostate cancer markers. The test may provide information about how aggressive the cancer is and which treatment options might be best.

Share